Pharmacogenetic Prediction of Individual Variability in Drug Response Based on CYP2D6, CYP2C9 and CYP2C19 Genetic Polymorphisms

By  

Current Drug Metabolism, Vol. 15, Iss. 7, 2014-09 ,pp. : 711-718

Bentham Science Publishers

Access to resources Recommend Favorite

CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population

By Scott Stuart A   Edelmann Lisa   Kornreich Ruth   Erazo Monica   Desnick Robert J  

Pharmacogenomics, Vol. 8, Iss. 7, 2007-07 ,pp. : 721-730

Future Medicine

Access to resources Recommend Favorite

Influence of CYP2C9 and CYP2D6 Polymorphisms on the Pharmacokinetics of Nateglinide in Genotyped Healthy Volunteers

By Kirchheiner J.  

Clinical Pharmacokinetics, Vol. 43, Iss. 4, 2004-01 ,pp. : 267-278

Adis International

Access to resources Recommend Favorite

The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype

By Al-Shurbaji Ayman   Säwe Juliette  

European Journal of Clinical Pharmacology, Vol. 57, Iss. 12, 2002-02 ,pp. : 877-881

Springer Publishing Company

Access to resources Recommend Favorite

In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6

By Weiss Johanna  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 378, Iss. 3, 2008-09 ,pp. : 275-282

Springer Publishing Company

Access to resources Recommend Favorite